Printer Friendly

Chemotherapy-related infections.

Levofloxacin prevented infections following chemotherapy for cancer in two recent studies, but concerns remain about emerging resistance.

In one randomized study of 760 patients with chemotherapy-induced neutropenia, Giampaolo Bucaneve, M.D., of Hospital Policlinico Monteluce, Perugia, Italy, and his colleagues found that levofloxacin reduced the risk of fever by 20%, lowered documented infections by 17%, and reduced bacteremias by up to 16% (N. Engl. J. Med. 2005;353:977-87).

In another randomized study of 1,565 chemotherapy patients, Michael Cullen, M.D., of the University of Birmingham (England) and colleagues found that levofloxacin reduced the incidence of fever, compared with placebo: 4% of treatment patients vs. 8% on placebo had at least one fever during the first chemotherapy course. Levofloxacin reduced infection, severe infection, and hospitalization for infection rates (N. Engl. J. Med. 2005;353:988-98).

In an editorial, Lindsey R. Baden, M.D., wrote that patients at greatest risk, the period of increased risk, and the likelihood of the emergence of resistant organisms need to be defined. Improvement in risk stratification will minimize unnecessary use of antimicrobials and preserve the benefits described in the two studies (N. Engl. J. Med. 2005;353:1052-4).
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CLINICAL CAPSULES
Author:Worcester, Sharon
Publication:Internal Medicine News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 15, 2005
Words:194
Previous Article:Cartilage-piercing infections.
Next Article:Wisdom teeth speed onset of periodontal disease: gum disease has been linked to stroke, heart and renal vascular disease, and obstetric complications.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters